Lactulose

Lactulose is a synthetic disaccharide comprising galactose and fructose in combination as 1,4-beta-galactosido-fructose. It is prepared from lactose and supplied for clinical use as a flavoured syrup* containing approximately 50% lactulose, together with smaller amounts of galactose and of unchanged lactose (about 7 g of each per 100 ml).

The intestinal mucosa possesses no disaccharidase capable of splitting lactulose into its component monosaccharides1, and only insignificant amounts are absorbed unchanged2. On reaching the colon, however, this sugar is metabolized by bacterial enzymes into carbon dioxide and low molecular weight acids (chiefly lactic and acetic)2,3. Thus in sufficient dosage lactulose lowers the faecal pH, and produces an osmotic and fermentative diarrhoea analogous to that observed in lactase-deficient subjects following the oral administration of lactose4,5.

Clinical interest in lactulose first arose when Petuely6 induced an increase in the faecal population of Lactobacillus bifidus by the administration of this sugar to adults and to bottle-fed infants. He postulated that this effect might prevent enteritis during broad-spectrum antibiotic therapy, and showed that lactulose could also be employed to treat chronic constipation4. Lactulose has been studied as a laxative in a double-blind controlled trial and has been found effective7. However, at present it appears to possess no significant advantages as an aperient over cheaper alternatives, and has therefore not achieved general acceptance for this purpose8.

A novel and ingenious therapeutic concept was introduced by Bircher and his colleagues9, namely, the use of lactulose to control chronic portal-systemic encephalopathy. The rationale of this form of treatment was credited by Bircher10 to Ingelfinger11 who had suggested that since lactulose produced an increase in colonic lactobacilli (which lack urease and other ammonia-generating enzymes1,2,12,13), there might in theory be a beneficial action in chronic portal systemic encephalopathy. In this disabling complication of advanced cirrhosis, nitrogenous substances, formed in the colon by bacterial action on protein, bypass the liver through natural or surgically formed vascular shunts and affect the brain14. Conventional therapy has hitherto required dietary protein restriction, purgation, and the administration of a broad-spectrum antibiotic, each of which has disadvantages. Prolonged dietary protein restriction is inconvenient and may be harmful; vigorous evacuation of the bowel by purgation or enemas may produce or exacerbate electrolyte disturbance15. Continuous administration of a broad-spectrum antibiotic such as neomycin may result in moniliasis, staphylococcal enterocolitis, or malabsorption of both sugars and fat16,17,18,19. Other measures less frequently employed include the oral administration of cultures of Lactobacillus acidophilus13, which involves the consumption of large quantities of protein, and surgical exclusion of the colon20,21, which carries a considerable

*‘Duphalac', Duphar Laboratories Ltd.
operative mortality. Thus the introduction of lactulose by Bircher and his coworkers\textsuperscript{9} was welcome.

Clinical Studies in Chronic Portal-systemic Encephalopathy

In the initial clinical study\textsuperscript{9} lactulose was administered to two patients in a dose sufficient to produce two soft bowel motions daily but insufficient to produce watery diarrhoea. Comparison was made with sorbitol as a control substance. (This sugar is not fermented in the bowel and has an osmotic action only on stool consistency.) Bircher and his colleagues\textsuperscript{9} reported that lactulose was as effective as neomycin in correcting encephalopathy, and possibly more so, since the dietary protein intake was greater during lactulose therapy. The only side effects were watery diarrhoea if the dose was too great—the optimum dose in their patients was 100-150 ml of the syrup daily in divided doses—and some initial abdominal distension and flatulence, which resolved within a few days. These workers\textsuperscript{9} postulated that the action of lactulose in preventing hepatic coma resulted primarily from a change in the colonic bacterial flora, in accordance with Ingelfinger's original hypothesis\textsuperscript{11}. Subsequently Markoff\textsuperscript{22} briefly reported the successful use of lactulose in one patient.

These promising reports stimulated several groups to study lactulose in greater detail. Fung and Khoo\textsuperscript{23} compared the response of two patients to lactulose and to conventional therapy, including neomycin. They concluded that lactulose was superior, since it provided better control of asterixis, allowed a normal protein intake, and was free from significant side effects in a dose of 90 ml daily. Lande and Clot-Paimboeuf\textsuperscript{24} reported improvement with lactulose in 10 out of 12 patients, but made no control comparisons. Rottiers and his associates\textsuperscript{25} reported uncontrolled observations on 11 patients with chronic portal-systemic encephalopathy, six of whom benefited from treatment with lactulose. The best responses were observed in patients whose clinical condition was stable, particularly when encephalopathy followed portacaval anastomosis.

The neuropsychiatric state of patients with chronic portal-systemic encephalopathy is notoriously unstable, and carefully controlled investigations are essential if therapy is to be evaluated accurately. The first double-blind controlled study\textsuperscript{26} compared the response of seven patients to treatment, which was randomly assigned, with lactulose and with sorbitol over short periods of one to two weeks. Five of these patients improved clinically during lactulose therapy but did not respond to sorbitol, the improvement correlating well with decreases in faecal pH and in arterial blood ammonia values. In two patients who did not improve with lactulose the faecal pH remained unaltered. Seven patients were also studied during lactulose administration lasting for several months. It was concluded that lactulose was effective in controlling chronic portal-systemic encephalopathy, enabling neomycin to be discontinued and protein intake to be doubled. In one instance chronic choreo-athetoid movements lessened. However, Ma and his colleagues\textsuperscript{27}, in an uncontrolled study of long-term lactulose therapy, did not observe benefit in two patients with evidence of extrapyramidal disease. These workers concluded, nevertheless, that improvement occurred in six out of eight treated patients. More recently, Bircher\textsuperscript{28} has reported improvement during lactulose therapy in six patients, and Rorsman and Sulg\textsuperscript{29} have reported an uncontrolled study of three patients, each of whom was controlled by lactulose as judged clinically and by electroencephalography.

Each of the foregoing studies lacked a statistical analysis of the many variables which had been followed in each subject, an omission which had
led some workers to express their conclusions with caution\textsuperscript{26}. This shortcoming was remedied by the elegant study of Zeegen and his coworkers\textsuperscript{30}, in which magnesium sulphate was used as a control. In addition to detailed investigations comprising daily faecal frequency, weight, and bacteriology, together with estimations of arterial and venous blood ammonia levels, these investigators employed a method of quantitative psychometric testing, the Reitan trail test, for serial evaluation of their patients. The difficulties of analysing daily data for different periods were overcome by using the cumulative sum technique. Clinical improvement occurred in three out of seven patients during lactulose therapy, and relapse followed substitution by magnesium sulphate. The patients who did not respond resembled those responding to treatment in respect of decreases in faecal pH and in blood ammonia, and the reason for their failure to improve was unexplained. It was concluded that lactulose can be a useful alternative to neomycin in some patients with chronic portal-systemic encephalopathy, particularly when prolonged treatment is required.

**Mode of Action**

The original hypothesis of Bircher and his colleagues\textsuperscript{9}, that lactulose acted by enhancing the growth of urease-deficient organisms such as lactobacilli, has not been supported by subsequent studies. Investigations undertaken in rats by Bircher and his associates\textsuperscript{31} demonstrated no increase in faecal urease activity following lactulose therapy, despite a rise in the number of anaerobic lactobacilli. In normal subjects given lactulose therapy, Flocch and coworkers\textsuperscript{38} were unable to detect any significant change in the pattern of faecal flora during the administration of lactulose to normal subjects, nor were significant changes observed during treatment of cirrhotic patients\textsuperscript{86}. In unselected hospital patients with various disorders who were given lactulose, Hoffman and his associates\textsuperscript{33} found significant decreases in total bacterial counts, *E. coli*, and Bacteroides, with no more than a proportional increase in lactobacilli and no alteration in faecal ammonia values. In cirrhotic patients lactulose produced clinical improvement one to three weeks before the development of consistent changes in faecal bacteriology, and benefit was obtained even by patients whose stools contained no lactobacilli. However, Mütting\textsuperscript{34} found a relative increase in lactobacilli in cirrhotic patients treated with lactulose, and Gmünder\textsuperscript{35} found no decrease in colonic bacterial urease activity in rats given lactulose. Zeegen and his colleagues\textsuperscript{30} observed significant increases in faecal lactobacilli during lactulose administration, but found no consistent changes in coliforms or in Bacteroides.

It is the opinion of most workers that changes in faecal flora cannot explain the clinical action of lactulose. Nor can the action be ascribed to the purgative effect of lactulose, since control substances such as sorbitol\textsuperscript{9,38} and magnesium sulphate\textsuperscript{30}, which have a purely laxative action, produce no clinical improvement.

A third mechanism by which lactulose may act is through trapping ammonia in the acidified contents of the bowel. Rottiers and coworkers\textsuperscript{25} have shown that the administration of lactulose improves both oral and intravenous ammonia tolerance, suggesting that lactulose indeed influences ammonia metabolism directly. Ammonia exists in blood predominantly as ammonium ion (NH\textsubscript{4}\textsuperscript{+}) and in small amounts as non-ionized ammonia (NH\textsubscript{3}). The ratio of these substances is largely determined by the blood pH, since the dissociation constant of ammonia (pKa 8.90 at 37°C)\textsuperscript{38} is sufficiently close to the physiological pH of blood for any change in the latter to affect the NH\textsubscript{4}\textsuperscript{+}/NH\textsubscript{3} ratio appreciably. Ionizable compounds in compartments
Lactulose is absorbed in insignificant amounts only, which are rapidly excreted by the kidney. It has no effects beyond the lumen of the bowel. On first receiving the syrup, patients frequently note borborygmi, an increase in flatus, and occasionally colicky abdominal discomfort, but these symptoms usually remit within a few days either spontaneously or on adjustment of the dose. Diarrhoea is the most important side effect, but also responds to reduction in the dose of lactulose. Most investigators have started treatment with 25-30 ml of syrup three times daily, and have adjusted the dose so as to obtain two or three semi-formed stools daily with a pH of 5.5 or less checked by indicator paper. Occasional patients require 150 ml daily or more, and a few are sensitive to daily doses of less than 100 ml. Acidification of the stool may be achieved without any looseness of the motion, but some patients may develop severe diarrhoea before the stool becomes acid and require withdrawal of lactulose. Patients may object to the sweet taste of the syrup or to the flavouring, but the majority find it an acceptable and palatable form of treatment. Long-term administration of lactulose has no adverse effects.

Conclusions

Lactulose is a useful addition to the existing treatment of cirrhotic patients with neuropsychiatric disorders. Most patients respond, particularly those with mild and relatively stable symptoms; such patients may receive lactulose...
indefinitely, and enjoy improved tolerance of dietary protein. However, unpredictable and inexplicable failures to respond occur, and lactulose cannot replace conventional measures for controlling chronic portal-systemic encephalopathy on all occasions in every patient. Though more expensive than neomycin, lactulose is free from significant side effects, and therefore falls into place as a valuable alternative to antibiotics when prolonged therapy is required. The probable mode of action is through acidification of the contents of the large bowel, resulting in the trapping and reabsorption of ammonia at this site. It is not recommended for the treatment of coma associated with fulminating hepatitis, in which ammonia intoxication is less important than in chronic portal-systemic encephalopathy.

S. G. ELKINGTON
King’s College Hospital, London

References

8. Bircher, J. Personal communication.


Gastroenterology, 58, 595-597.


Gastroenterology, 58, 595-597.

Elkington, S. G. Unpublished observations.

Lactulose.

S G Elkington

Gut 1970 11: 1043-1048
doi: 10.1136/gut.11.12.1043

Updated information and services can be found at: http://gut.bmj.com/content/11/12/1043.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Diarrhoea (663)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/